Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer

Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.

(2017) T. Ohnuma et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiologic and survival characteristics of breast cancer (BC) among the U.S. Asian Indian and Pakistani women compared with other U.S. population groups: A SEER database study.

(2017) Shahzad Raza et al.   JOURNAL OF CLINICAL ONCOLOGY

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo

(2015) Brian A. DeChristopher et al.   Oncotarget

ON 01910.Na

(2014) D.R. Taft et al.   DRUGS OF THE FUTURE

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation

(2013) Carolyn Bentley et al.   BIOCHEMICAL JOURNAL

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

(2013) Rami S. Komrokji et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition

(2013) Daniel J. Goff et al.   Cell Stem Cell

Noncanonical roles of the immune system in eliciting oncogene addiction

(2013) Stephanie C Casey et al.   CURRENT OPINION IN IMMUNOLOGY

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors

(2013) Håkon Reikvam et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions

(2013) David A. Drew et al.   PROTEOMICS

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

(2012) C. M. Chapman et al.   CLINICAL CANCER RESEARCH

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

(2012) W. W. Ma et al.   CLINICAL CANCER RESEARCH

Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

(2012) Galina Tsykunova et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The F-BAR Protein PACSIN2 Regulates Epidermal Growth Factor Receptor Internalization

(2012) Bart-Jan de Kreuk et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Six1 regulates stem cell repair potential and self-renewal during skeletal muscle regeneration

(2012) Fabien Le Grand et al.   JOURNAL OF CELL BIOLOGY

Intravascular B-Cell Lymphoma: An Elusive Diagnosis

(2012) Muhammad Raza et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd

(2012) Zuyue Sun et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

(2012) Matthew J. Olnes et al.   LEUKEMIA RESEARCH

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

Clonal Architecture of Secondary Acute Myeloid Leukemia

(2012) Matthew J. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line

(2011) Noemi Kedei et al.   BIOCHEMICAL PHARMACOLOGY

Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation

(2011) I. A. Oussenko et al.   CANCER RESEARCH

Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction

(2011) P. Bachireddy et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity

(2011) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

(2011) Mahesh Seetharam et al.   LEUKEMIA RESEARCH

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

(2011) P. S. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

(2010) Håkon Reikvam et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

(2010) Sébastien Albert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity

(2010) Øystein Bruserud et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer

(2010) A. Jimeno et al.   MOLECULAR CANCER THERAPEUTICS

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Targeted therapy in acute myeloid leukaemia: current status and future directions

(2009) Camilla Stapnes et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

(2009) Alice C Fan et al.   NATURE MEDICINE

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

(2009) A Prasad et al.   ONCOGENE

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

(2008) Sharmila Patel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay

(2008) A Jimeno et al.   ONCOGENE